Navigation Links
Histogen Wins Appellate Court Hearing in SkinMedica Patent Case
Date:8/26/2013

San Diego, CA (PRWEB) August 26, 2013

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that the United States Court of Appeals for the Federal Circuit has affirmed a lower court decision that the Company does not infringe patents in the lawsuit that SkinMedica, Inc. filed against Histogen in 2009.

SkinMedica had previously sued the Company for infringement of United States Patent Nos. 6,372,494 (titled “Methods of making conditioned cell culture medium compositions”) and 7,118,746 (titled “Conditioned cell culture medium compositions and methods of use”). In 2011, the United States District Court for the Southern District of California granted the Company’s Motion for Summary Judgment, confirming a finding of noninfringement. SkinMedica appealed the Summary Judgment Order, and on August 23, 2013 was rebuffed again by the Federal Circuit.

“We are excited to have confirmation from the Federal Circuit Court of Appeals that Histogen’s technology is unique, and outside of SkinMedica’s patent rights,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “We look forward to continuing the rapid revenue growth we’re seeing in our skincare business through our current partners, bringing on new partners in the near future, and expanding the skin care line to other aesthetic applications.”

Histogen’s proprietary human multipotent cell conditioned media is the key ingredient in the ReGenica line of skincare products within the United States, and will be incorporated into additional cosmetic products in various countries through promising partnerships.

The Federal Circuit Court of Appeals affirmed the grant of Motion for Summary Judgment in case 2012-1560 following a hearing on May 9, 2013. A copy of the appellate court opinion is available upon request.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11059251.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
2. Genetic Testing Explodes after Supreme Court Patent Decision
3. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
4. Honey Bee Beekeeping Class at North Island College’s Courtenay Campus
5. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
6. Bed Bugs are On The Rise in Courts and Apartment Complexes; My Cleaning Products Offers Complimentary Samples of Its Bed Bug Spray To Bed Bug Victims
7. Non-Toxic Bed Bug Spray Offers Complimentary Sample to Court After a Man Infected It With Bed Bugs, My Cleaning Products Explains How Others Could Get a Sample
8. Indoor Air Quality Professionals Provide New Expert Witness Services To Help Mold Victims Get Mold Claims Approved and Win in Court, AGCEnvironmental Explains How
9. Case Zeltiq - CLINIPRO: The Court Upholds Clinipro - LipoCryo Claim
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... ... from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ ... a test on mice, MSC-EVs also increased the cells’ ability to lodge into ...
(Date:5/31/2019)... ... 29, 2019 , ... For many years, the primary forms of cancer treatment ... therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T ... cell receptors known as “CARs”. The CAR enables the final product to produce chemicals ...
(Date:5/31/2019)... ... May 30, 2019 , ... World Compliance Seminars today ... 08-09, 2019 in Boston, MA. This peer recommended interactive workshop is always selected ... training will kick off with a compendial treatment of Data Integrity fundamentals. After ...
(Date:5/31/2019)... ... 30, 2019 , ... A study released today in STEM ... the sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) to ... CM into the injured kidney, where it helped restore function and regenerate injured ...
Breaking Biology Technology:
(Date:6/4/2019)... ... 04, 2019 , ... Harper was three years old when her owners took ... which caused painful osteoarthritis in the joints. She was referred to a veterinary ... The surgical specialist, Dr. Christopher Eich of Southern California Veterinary Specialty Hospital , ...
(Date:6/3/2019)... ... , ... Stay on top of current hot topics through free webinars presented ... webinars is free, so be sure to register today to save your place! Participate ... to see our upcoming webinars: , CLINICAL TRIALS , June 10 – A Novel ...
(Date:5/31/2019)... , ... May 30, 2019 , ... ... testing company, and Mayo Clinic, have documented significant differences in the prevalence of ... and ethnic populations compared to non-Hispanic White women. Results will be presented at ...
Breaking Biology News(10 mins):